Please assess the completion status of the following clinical trial:

Trial Title: Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Gestation of at least 16 weeks and \<37 weeks;~* P. falciparum monoinfection of any density, with or without symptoms~* Hb equal or higher than 7 g/dL;~* At least 15 years old;~* Residence within the health facility catchment's area;~* Willing to deliver at the health facility;~* Willing to adhere to study requirements (including in Zambia and Malawi, HIV VCT)~* Ability to provide written informed consent; if the woman is minor of age/not emancipated, the consent must be given by a parent or legal guardian according to national law (however, in this case, the investigator is responsible to check that the woman herself is also freely willing to take part in the study, and the woman will be asked to sign for assent).~Exclusion Criteria:~* History of allergic reactions to the study drugs;~* History of known pregnancy complications or bad obstetric history such as repeated stillbirths or eclampsia;~* History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis;~* Current cotrimoxazole prophylaxis or ARV treatment;~* Any significant illness at the time of screening that requires hospitalization, including severe malaria;~* Intent to move out of the study catchment area before delivery or deliver at relative's home out of the catchment area.~* Prior enrollment in the study or concurrent enrollment in another study.~* Unable to take oral medication~* Clear evidence of recent (1 week) treatment with antimalarials or antimicrobials with antimalarial activity (clindamycin; azythromycin; etc.)

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHAPQ (Type: EXPERIMENTAL): Three-day treatment with dihydroartemisinin-piperaquine
- MQAS (Type: EXPERIMENTAL): Three-day treatment with mefloquine artesunate
- AQAS (Type: ACTIVE_COMPARATOR): Three-day treatment with artesunate-amodiaquine
- AL (Type: ACTIVE_COMPARATOR): Three day treatment with artemether-lumefantrine (Coartem(R)

Based on this trial design, predict the completion outcome and termination type (if applicable).